KimerDx wins Venture Challenge
Fall 2013
Advanced technologies for post-transplant monitoring improves patient
care
December 2, 2013
Molecular diagnostics start-up KimerDx is the winner of the Venture
Challenge Fall 2013, which includes €25,000 prize money. KimerDx
develops advanced technologies that allow early detection of rejection
or disease relapse in transplant patients. Six teams participated in
this edition of the Venture Challenge, an intensive track for life
sciences start-ups.
Together
the teams covered
a broad range of life sciences topics, ranging from animal-free methods
for toxicity testing to novel polymers for minimally invasive knee
surgery and from medical food products for patients with weakened immune
systems to new analysis methods for complex biological data.
According to
the jury, consisting of established life sciences experts, the team
behind KimerDx is experienced, diverse and highly motivated. One of the
members is a seasoned entrepreneur who knows the industry very well and
the team has already managed to secure external funding. Moreover,
KimerDx is tackling a clear market need as key opinion leaders in the
fields of both stem cell and organ transplantation have stated. New methods
to improve post-transplant monitoring are urgently needed and KimerDx is
proposing a feasible solution.
About KimerDx
In transplant medicine, early detection of transplant rejection or
disease relapse is critical for the adjustment of the patient's
treatment regime, graft survival and overall quality of life. KimerDx
focuses on developing and commercialising advanced technologies that can
change the way transplant medicine is practised today. Clinical testing
has demonstrated that adverse events may be detected 3-4 months earlier
using the approaches offered by KimerDx compared to the current Golden
Standard monitoring methods. KimerDx's solutions will enable new
applications, which will result in improved patient care and survival
rates.
www.kimerdx.com |